More Neurotech International Ltd. news
Neurotech International Ltd.ASX: NTI

NTI granted HREC Approval for PANDAS/PANS Trial Extension

May 29, 2023 at 11:44 PM EDT · Issued by Neurotech International Ltd.

Filed with ASX · May 29, 2023 at 11:44 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/nti-granted-hrec-approval-for-pandaspans-trial-extension

Neurotech International Ltd. on 6ix

Story so far

  • HREC Approval for Phase I/II PANDAS/PANS Clinical TrialJan 27, 2023
  • NTI Receives HREC/TGA Approval for Phase II/III ASD TrialNov 17, 2022

Earlier from Neurotech International

  • NTI Completes Recruitment in PANDAS/PANS Clinical TrialMay 2, 2023
  • NTI to Launch Phase II Clinical Trial in Rett SyndromeMar 19, 2023
  • Phase I/II ASD Clinical Trials Results at 52 WeeksMar 16, 2023
  • First Patient Treated in Phase I/II PANDAS/PANS TrialFeb 16, 2023
  • Approval for Additional Phase I/II ASD Trial ExtensionFeb 13, 2023

Later from Neurotech International

  • NTI Granted 2 Year Extension of Treatment for ASD PatientsMay 30, 2023
  • NTI Receives HREC Approval for Rett Syndrome Clinical TrialJul 9, 2023
  • First Patient Treated in Rett Syndrome Clinical TrialAug 1, 2023
  • Appendix 4E & Annual ReportAug 30, 2023
  • Last Patient Completes Treatment in NTIPANS1 Clinical TrialAug 30, 2023
All Neurotech International news releases↗

Follow Neurotech International into a list and get an email when it puts out news.

Follow Neurotech International
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer